- Home
- LSBK vs ARMP Comparison
LSBK vs ARMP Comparison
Compare LSBK & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- ARMP
- Stock Information
- Founded
- LSBK 1891
- ARMP N/A
- Country
- LSBK United States
- ARMP United States
- Employees
- LSBK N/A
- ARMP N/A
- Industry
- LSBK Savings Institutions
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSBK Finance
- ARMP Health Care
- Exchange
- LSBK Nasdaq
- ARMP Nasdaq
- Market Cap
- LSBK 90.0M
- ARMP 52.1M
- IPO Year
- LSBK 2006
- ARMP N/A
- Fundamental
- Price
- LSBK $15.93
- ARMP $2.17
- Analyst Decision
- LSBK
- ARMP Strong Buy
- Analyst Count
- LSBK 0
- ARMP 1
- Target Price
- LSBK N/A
- ARMP $9.00
- AVG Volume (30 Days)
- LSBK 3.3K
- ARMP 22.0K
- Earning Date
- LSBK 07-23-2025
- ARMP 08-12-2025
- Dividend Yield
- LSBK 3.39%
- ARMP N/A
- EPS Growth
- LSBK 27.62
- ARMP N/A
- EPS
- LSBK 0.89
- ARMP N/A
- Revenue
- LSBK $25,795,000.00
- ARMP $4,699,000.00
- Revenue This Year
- LSBK N/A
- ARMP $8.43
- Revenue Next Year
- LSBK N/A
- ARMP N/A
- P/E Ratio
- LSBK $17.84
- ARMP N/A
- Revenue Growth
- LSBK N/A
- ARMP 14.24
- 52 Week Low
- LSBK $11.80
- ARMP $0.90
- 52 Week High
- LSBK $16.95
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- LSBK 60.76
- ARMP 62.40
- Support Level
- LSBK $15.68
- ARMP $1.85
- Resistance Level
- LSBK $16.09
- ARMP $2.00
- Average True Range (ATR)
- LSBK 0.08
- ARMP 0.16
- MACD
- LSBK 0.00
- ARMP 0.00
- Stochastic Oscillator
- LSBK 63.64
- ARMP 86.00
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.